BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 36622123)

  • 1. Anti-TIF1-γ antibody-positive dermatomyositis caused by camrelizumab in a patient with oesophageal cancer.
    Li J; Yi S; Huang Y; Peng Y; Yang Z
    Clin Exp Rheumatol; 2023 Mar; 41(2):395. PubMed ID: 36622123
    [No Abstract]   [Full Text] [Related]  

  • 2. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.
    Huang J; Xu J; Chen Y; Zhuang W; Zhang Y; Chen Z; Chen J; Zhang H; Niu Z; Fan Q; Lin L; Gu K; Liu Y; Ba Y; Miao Z; Jiang X; Zeng M; Chen J; Fu Z; Gan L; Wang J; Zhan X; Liu T; Li Z; Shen L; Shu Y; Zhang T; Yang Q; Zou J;
    Lancet Oncol; 2020 Jun; 21(6):832-842. PubMed ID: 32416073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating VEGF-A, TNF-α, CCL2, IL-6, and IFN-γ as biomarkers of cancer in cancer-associated anti-TIF1-γ antibody-positive dermatomyositis.
    Li X; Huang Y; Liu Y; Yan S; Li L; Cheng L; Li H; Zhan H; Zhang F; Li Y
    Clin Rheumatol; 2023 Mar; 42(3):817-830. PubMed ID: 36357631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-TIF1γ antibody-positive dermatomyositis associated with nivolumab administration in a patient with advanced oesophageal squamous cell carcinoma: A case report and literature review.
    Sakurai T; Takahashi J; Komatsu T; Mitsumura H; Iguchi Y
    Mod Rheumatol Case Rep; 2023 Jun; 7(2):416-421. PubMed ID: 36715286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical features of anti-TIF1-α antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-γ or anti-Mi-2 autoantibodies.
    Muro Y; Ishikawa A; Sugiura K; Akiyama M
    Rheumatology (Oxford); 2012 Aug; 51(8):1508-13. PubMed ID: 22539482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial.
    Luo H; Lu J; Bai Y; Mao T; Wang J; Fan Q; Zhang Y; Zhao K; Chen Z; Gao S; Li J; Fu Z; Gu K; Liu Z; Wu L; Zhang X; Feng J; Niu Z; Ba Y; Zhang H; Liu Y; Zhang L; Min X; Huang J; Cheng Y; Wang D; Shen Y; Yang Q; Zou J; Xu RH;
    JAMA; 2021 Sep; 326(10):916-925. PubMed ID: 34519801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Camrelizumab induced myocarditis in the treatment of esophageal carcinoma: a case report].
    Wang Q; Yuan W; Wen HB; Li L
    Zhonghua Zhong Liu Za Zhi; 2022 Feb; 44(2):201-202. PubMed ID: 35184467
    [No Abstract]   [Full Text] [Related]  

  • 8. Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial.
    Meng X; Wu T; Hong Y; Fan Q; Ren Z; Guo Y; Yang X; Shi P; Yang J; Yin X; Luo Z; Xia J; Zhou Y; Xu M; Liu E; Jiang G; Li S; Zhao F; Ma C; Ma C; Hou Z; Li J; Wang J; Wang F
    Lancet Gastroenterol Hepatol; 2022 Mar; 7(3):245-253. PubMed ID: 34998471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case of pembrolizumab-induced dermatomyositis with anti-transcription intermediary factor 1-γ antibody.
    Mizumaki K; Makino S; Ikawa Y; Maeda S; Horii M; Fushida N; Hamaguchi Y; Nohara T; Izumi K; Matsushita T
    J Dermatol; 2022 Sep; 49(9):e311-e312. PubMed ID: 35546739
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical significance of anti-transcriptional intermediary factor 1-γ antibody in patients with dermatomyositis: a monocentric cross-sectional study.
    Yang H; Yan T; Zhang X; Sun W; Liu L; Du Y; Xue J
    Clin Rheumatol; 2022 Aug; 41(8):2439-2448. PubMed ID: 35422109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-transcriptional intermediary factor 1 gamma antibodies in cancer-associated myositis: a longitudinal study.
    Dani L; Holmqvist M; Martínez MA; Trallero-Araguas E; Dastmalchi M; Svensson J; Labrador-Horrillo M; Selva-O'Callaghan A; Lundberg IE
    Clin Exp Rheumatol; 2020; 38(1):67-73. PubMed ID: 31365334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis induced by nivolumab for lung adenocarcinoma: A case report.
    Osaki M; Tachikawa R; Ohira J; Hara S; Tomii K
    Invest New Drugs; 2021 Feb; 39(1):251-255. PubMed ID: 32651759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Case in Which Breast Cancer Developed at the Same Time As Dermatomyositis, and the Onset of New Cancer Was Able to Be Predicted by the Exacerbating Skin Symptoms and Parallel Increase in the Anti-TIF1-γ Antibody Levels.
    Akagi H; Wada T
    Intern Med; 2023; 62(20):3057-3062. PubMed ID: 37839875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of distinct cytokine/chemokine profiles in dermatomyositis with anti-transcriptional intermediary factor 1-γ antibody.
    Zhao Q; Chen Y; Diao L; Zhang S; Wu D; Xue F; Xia Q; Li H; Zheng J; Cao H
    Rheumatology (Oxford); 2022 May; 61(5):2176-2184. PubMed ID: 34508564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of serum levels of anti-transcriptional intermediary factor 1-γ antibody in patients with dermatomyositis.
    Ikeda N; Yamaguchi Y; Kanaoka M; Ototake Y; Akita A; Watanabe T; Aihara M
    J Dermatol; 2020 May; 47(5):490-496. PubMed ID: 32103537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current Status and Prospects of Camrelizumab, A Humanized Antibody Against Programmed Cell Death Receptor 1.
    Song H; Liu X; Jiang L; Li F; Zhang R; Wang P
    Recent Pat Anticancer Drug Discov; 2021; 16(3):312-332. PubMed ID: 33563158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-transcriptional intermediary factor 1-γ antibody as a biomarker in patients with dermatomyositis.
    Shimizu K; Kobayashi T; Kano M; Hamaguchi Y; Takehara K; Matsushita T
    J Dermatol; 2020 Jan; 47(1):64-68. PubMed ID: 31638280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dermatomyositis associated with anti-tumor necrosis factor therapy in a patient with psoriasis.
    Dicaro D; Bowen C; Dalton SR
    J Am Acad Dermatol; 2014 Mar; 70(3):e64-5. PubMed ID: 24528921
    [No Abstract]   [Full Text] [Related]  

  • 19. Characteristics of anti-transcriptional intermediary factor 1 gamma autoantibody-positive dermatomyositis patients in Singapore.
    Chua CG; Low JZ; Lim WY; Manghani M
    Ann Acad Med Singap; 2022 Dec; 51(12):755-765. PubMed ID: 36592144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumor necrosis factor inhibitor therapy-induced dermatomyositis and fasciitis.
    Riolo G; Towheed TE
    J Rheumatol; 2012 Jan; 39(1):192-4. PubMed ID: 22210682
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.